Should cancers that are not traditionally associated with Lynch syndrome or MSI-H status be tested? This expert thinks so.
Microsatellite instability-high (MSI-H) status is often predictive of Lynch syndrome, two biomarkers that are typically associated with colorectal and endometrial cancer. However, perhaps patients with other kinds of cancers should be tested, too, according to Alicia Latham Schwark, M.D., a medical genetics fellow at Memorial Sloan Kettering Cancer Center.
Now that there are some immunotherapy drugs that are showing promise in MSI-H tumors, there has been an increase in the number of patients who are being tested. This might open the doors to new discoveries of Lynch syndrome and MSI-H in other cancers, which could have major implications for patients and their families.
Traditional Definition of ‘High-Risk’ in Patients With CLL and SLL Outdated, Needs to be Revisited
December 7th 2020In an interview with CURE®, Dr. Jan A. Burger discusses how the results of two phase 3 studies could help redefine what constitutes as low or high risk in patients with CLL or SLL.
Read More
To gain a better understanding of the issues faced by geriatric patients with cancer, and to determine how much of a role nutrition plays in outcomes, Dr. Grant Williams, a geriatrician oncologist and assistant professor at the University of Alabama, Birmingham, worked with colleagues to create a patient-reported assessment tool that bridges the knowledge gap in this patient population.
Read More